NASDAQ
2.13USD
+0.01 (+0.71%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
135.6M
P/E
—
EPS
—
Beta
-0.01
52W range
0.41-3.9
Day range
2.13–2.13
Open
2.13
Prev close
2.12
Volume
66.8K
Avg volume
580.1K
Dividend
0.00
IPO
2013-02-22
https://www.prnewswire.com/news-releases/tuhura-biosciences-to-present-at-canaccord-genuitys-46th-annual-growth-conference-302831522.html · 7/22/2026+0.20
https://www.prnewswire.com/news-releases/tuhura-biosciences-files-investigational-new-drug-application-for-evaluation-of-the-tbs-2025-vista-inhibiting-antibody-in-molecularly-defined-subsets-of-aml-and-other-blood-related-cancers-302799770.html · 6/15/2026+0.80
https://www.prnewswire.com/news-releases/tuhura-biosciences-appoints-amanda-garofalo-mshs-as-senior-vice-president-of-clinical-operations-302735470.html · 4/7/2026+0.80
https://www.prnewswire.com/news-releases/tuhura-biosciences-discovery-research-on-targeting-the-delta-opioid-receptor-dor-to-reprogram-myeloid-derived-suppressor-cells-mdscs-selected-for-oral-presentation-at-the-67th-ash-annual-meeting-and-exposition-302602298.html · 11/3/2025
TuHURA Biosciences, Inc. is an immuno-oncology firm that has reached the critical Phase 3 registration stage of clinical development. The company is dedicated to pioneering innovative technologies designed to effectively combat the mechanisms by which cancers develop resistance to existing immunotherapy treatments. Its operations are based in Tampa, Florida.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
